[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CY1116578T1 - Αναστολεις της bromodomain και χρησεις αυτων - Google Patents

Αναστολεις της bromodomain και χρησεις αυτων

Info

Publication number
CY1116578T1
CY1116578T1 CY20151100688T CY151100688T CY1116578T1 CY 1116578 T1 CY1116578 T1 CY 1116578T1 CY 20151100688 T CY20151100688 T CY 20151100688T CY 151100688 T CY151100688 T CY 151100688T CY 1116578 T1 CY1116578 T1 CY 1116578T1
Authority
CY
Cyprus
Prior art keywords
bromodomain
suspensions
present
compositions
compounds
Prior art date
Application number
CY20151100688T
Other languages
English (en)
Inventor
Brian K Albrecht
James Edmund Audia
Alexandre Côté
Victor S Gehling
Jean-Christophe Harmange
Michael C Hewitt
Yves Leblanc
Christopher G Nasveschuk
Alexander M Taylor
Rishi G Vaswani
Original Assignee
Constellation Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Constellation Pharmaceuticals, Inc. filed Critical Constellation Pharmaceuticals, Inc.
Publication of CY1116578T1 publication Critical patent/CY1116578T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/424Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται σε ενώσεις χρήσιμες ως αναστολείς πρωτεϊνών που περιέχουν την περιοχή bromodomain. Η εφεύρεση παρέχει επίσης φαρμακευτικώς αποδεκτές συνθέσεις περιέχουσες ενώσεις της παρούσας εφεύρεσης και μεθόδους χρησιμοποίησης των ρηθέντων συνθέσεων στη θεραπευτική αγωγή διαφόρων διαταραχών.
CY20151100688T 2010-12-02 2015-08-06 Αναστολεις της bromodomain και χρησεις αυτων CY1116578T1 (el)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US41911910P 2010-12-02 2010-12-02
US201161451332P 2011-03-10 2011-03-10
US201161482473P 2011-05-04 2011-05-04
US201161540788P 2011-09-29 2011-09-29
US201161540725P 2011-09-29 2011-09-29
EP11844513.9A EP2646446B1 (en) 2010-12-02 2011-12-02 Bromodomain inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
CY1116578T1 true CY1116578T1 (el) 2017-03-15

Family

ID=46235164

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20151100688T CY1116578T1 (el) 2010-12-02 2015-08-06 Αναστολεις της bromodomain και χρησεις αυτων

Country Status (27)

Country Link
US (2) US8796261B2 (el)
EP (1) EP2646446B1 (el)
JP (1) JP5850944B2 (el)
KR (1) KR101871013B1 (el)
CN (1) CN103415525B (el)
AR (1) AR084070A1 (el)
AU (1) AU2011336417B2 (el)
BR (1) BR112013013167B1 (el)
CA (1) CA2818187C (el)
CY (1) CY1116578T1 (el)
DK (1) DK2646446T3 (el)
EA (1) EA022645B1 (el)
ES (1) ES2545117T3 (el)
HK (1) HK1189587A1 (el)
HR (1) HRP20150858T1 (el)
HU (1) HUE025321T2 (el)
IL (1) IL226331A (el)
MX (1) MX2013006214A (el)
NZ (1) NZ611964A (el)
PL (1) PL2646446T3 (el)
PT (1) PT2646446E (el)
RS (1) RS54175B1 (el)
SG (1) SG190739A1 (el)
SI (1) SI2646446T1 (el)
TW (1) TWI572607B (el)
WO (1) WO2012075383A2 (el)
ZA (1) ZA201303776B (el)

Families Citing this family (144)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101444489B1 (ko) 2007-02-01 2014-09-24 리스버로직스 코퍼레이션 심혈관 질환을 예방 및 치료하기 위한 화합물
WO2010106436A2 (en) 2009-03-18 2010-09-23 Resverlogix Corp. Novel anti-inflammatory agents
DK2571503T3 (en) 2010-05-14 2015-04-20 Dana Farber Cancer Inst Inc COMPOSITIONS AND THEIR USE IN THE TREATMENT OF NEOPLASIA, INFLAMMATORY DISEASE AND OTHER DISORDERS
CA2799381A1 (en) 2010-05-14 2011-11-17 Dana-Farber Cancer Institute, Inc. Male contraceptive compositions and methods of use
JP5935030B2 (ja) 2010-05-14 2016-06-15 ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド 白血病を治療するための組成物および方法
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
WO2012075456A1 (en) 2010-12-02 2012-06-07 Constellation Pharmaceuticals Bromodomain inhibitors and uses thereof
US8912221B2 (en) * 2010-12-27 2014-12-16 Hoffmann-La Roche Inc. Biaryl amide derivatives
US9422292B2 (en) 2011-05-04 2016-08-23 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
WO2012174487A2 (en) 2011-06-17 2012-12-20 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
WO2013027168A1 (en) 2011-08-22 2013-02-28 Pfizer Inc. Novel heterocyclic compounds as bromodomain inhibitors
WO2013033269A1 (en) 2011-08-29 2013-03-07 Coferon, Inc. Bioorthogonal monomers capable of dimerizing and targeting bromodomains and methods of using same
WO2013033268A2 (en) 2011-08-29 2013-03-07 Coferon, Inc. Bivalent bromodomain ligands, and methods of using same
RS58911B1 (sr) 2011-11-01 2019-08-30 Resverlogix Corp Oralne formulacije sa trenutnim otpuštanjem za supstituisane hinazolinone
RU2666530C2 (ru) 2012-01-12 2018-09-11 Йейл Юниверсити Соединения и способы усиления деградации белков-мишеней и других полипептидов с помощью е3 убиквитин лигазы
WO2013184878A1 (en) 2012-06-06 2013-12-12 Constellation Pharmaceuticals, Inc. Benzo [b] isoxazoloazepine bromodomain inhibitors and uses thereof
TWI602820B (zh) 2012-06-06 2017-10-21 星宿藥物公司 溴域抑制劑及其用途
EP2858982A4 (en) * 2012-06-12 2015-11-11 Abbvie Inc PYRIDINONE AND PYRIDAZINONE DERIVATIVES
ES2628005T3 (es) 2012-08-16 2017-08-01 Bayer Pharma Aktiengesellschaft 2,3-Benzodiazepinas
CN104781259B (zh) 2012-09-28 2018-06-01 拜耳制药股份公司 抑制bet蛋白的5-芳基三唑并氮杂*
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
WO2014080290A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Cyclic amines as bromodomain inhibitors
KR20150096794A (ko) * 2012-12-21 2015-08-25 제니쓰 에피제네틱스 코포레이션 브로모도메인 저해제로서의 신규한 헤테로사이클릭 화합물
CN105263919A (zh) 2013-02-19 2016-01-20 拜耳医药股份有限公司 二环2,3-苯并二氮杂*和螺环取代的2,3-苯并二氮杂*
CA2901799A1 (en) 2013-02-22 2014-08-28 Bayer Pharma Aktiengesellschaft Pyrrolo- and pyrazolo-triazolodiazepines as bet-protein inhibitors for treating hyperproliferative diseases
EP2958923A1 (de) 2013-02-22 2015-12-30 Bayer Pharma Aktiengesellschaft 4-substituierte pyrrolo- und pyrazolo-diazepine
WO2014134583A2 (en) * 2013-02-28 2014-09-04 Washington University Methods of treatment of human cytomegalovirus infection and diseases with bromodomain inhibitors
WO2014164596A1 (en) 2013-03-11 2014-10-09 The Regents Of The University Of Michigan Bet bromodomain inhibitors and therapeutic methods using the same
US8980879B2 (en) * 2013-03-11 2015-03-17 Abbvie Inc. Bromodomain inhibitors
AU2014231563A1 (en) * 2013-03-12 2015-09-17 Abbvie Inc. Tetracyclic bromodomain inhibitors
EA201591746A1 (ru) * 2013-03-14 2016-08-31 КОНВЕРДЖЕН ЭлЭлСи Способы и композиции для ингибирования бромодомен-содержащих белков
US9714946B2 (en) 2013-03-14 2017-07-25 Dana-Farber Cancer Institute, Inc. Bromodomain binding reagents and uses thereof
KR102216288B1 (ko) 2013-03-15 2021-02-18 인사이트 홀딩스 코포레이션 Bet 단백질 저해제로서의 삼환식 복소환
BR112015027130A2 (pt) 2013-04-26 2018-07-24 Beigene Ltd 5-(3,5-dimetilisoxazol-4-il)indolin-2-ona substituído
TWI527811B (zh) * 2013-05-09 2016-04-01 吉李德科學股份有限公司 作爲溴結構域抑制劑的苯並咪唑衍生物
US8975417B2 (en) * 2013-05-27 2015-03-10 Novartis Ag Pyrazolopyrrolidine derivatives and their use in the treatment of disease
EP3004108B1 (en) * 2013-05-28 2017-10-18 Novartis AG Pyrazolo-pyrrolidin-4-one derivatives as bet inhibitors and their use in the treatment of disease
CA2913741A1 (en) * 2013-05-28 2014-12-04 The Brigham And Women's Hospital, Inc. Bet inhibition therapy for heart disease
ES2806135T3 (es) 2013-06-21 2021-02-16 Zenith Epigenetics Ltd Nuevos inhibidores de bromodominios bicíclicos
JP6461118B2 (ja) 2013-06-21 2019-01-30 ゼニス・エピジェネティクス・リミテッドZenith Epigenetics Ltd. ブロモドメイン阻害剤としての新規の置換された二環式化合物
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
EP3019502B1 (en) 2013-07-08 2017-05-17 Incyte Holdings Corporation Tricyclic heterocycles as bet protein inhibitors
CA2918910A1 (en) 2013-07-25 2015-01-29 Dana-Farber Cancer Institute, Inc. Inhibitors of transcription factors and uses thereof
US9855271B2 (en) 2013-07-31 2018-01-02 Zenith Epigenetics Ltd. Quinazolinones as bromodomain inhibitors
JP6453877B2 (ja) * 2013-08-01 2019-01-16 オンコエシックス ゲーエムベーハー チエノトリアゾロジアゼピン化合物を含む医薬製剤
JP2016529246A (ja) * 2013-08-06 2016-09-23 オンコエシックス ゲーエムベーハー Betブロモドメイン阻害剤を用いるびまん性大細胞型b細胞性リンパ腫(dlbcl)の治療方法
KR20160072261A (ko) * 2013-11-08 2016-06-22 다나-파버 캔서 인스티튜트 인크. 브로모도메인 및 엑스트라-말단 (bet) 단백질 저해제를 이용한 암 치료를 위한 조합 요법
US9315501B2 (en) 2013-11-26 2016-04-19 Incyte Corporation Bicyclic heterocycles as BET protein inhibitors
US9399640B2 (en) 2013-11-26 2016-07-26 Incyte Corporation Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
EP3080132A4 (en) * 2013-12-10 2017-08-02 AbbVie Inc. Bromodomain inhibitors
US9309246B2 (en) 2013-12-19 2016-04-12 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
WO2015117053A1 (en) 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Diaminopyrimidine benzenesulfone derivatives and uses thereof
US10793571B2 (en) 2014-01-31 2020-10-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
MX2016009976A (es) 2014-01-31 2016-11-15 Dana Farber Cancer Inst Inc Derivados de diazepam y sus usos.
WO2015121227A1 (de) * 2014-02-14 2015-08-20 Bayer Pharma Aktiengesellschaft 6,9-disubstituierte 1 -phenyl-3h-2,3-benzodiazepine und ihre verwendung als bromodomänen- inhibitoren
WO2015121268A1 (de) * 2014-02-14 2015-08-20 Bayer Pharma Aktiengesellschaft 1-phenyl-3h-2,3-benzodiazepine und ihre verwendung als bromodomänen-inhibitoren
JP2017071553A (ja) * 2014-02-25 2017-04-13 味の素株式会社 ヘテロ原子−メチレン−ヘテロ環構造を有する新規化合物
SG11201607108XA (en) 2014-02-28 2016-09-29 Tensha Therapeutics Inc Treatment of conditions associated with hyperinsulinaemia
AU2015222887B2 (en) 2014-02-28 2019-06-27 The Regents Of The University Of Michigan 9H-pyrimido[4,5-b]indoles and related analogs as BET bromodomain inhibitors
WO2015153871A2 (en) * 2014-04-04 2015-10-08 Constellation Pharmaceuticals, Inc. EXPRESSION LEVELS OF BCL-xL, BCL2, BCL-w, AND BAD AND CANCER THERAPIES
WO2015156601A1 (en) * 2014-04-09 2015-10-15 Kainos Medicine, Inc. Bromodomain-inhibiting compounds and pharmaceutical composition comprising same for preventing or treating a cancer
CA2946731C (en) 2014-04-23 2022-06-07 Incyte Corporation 1h-pyrrolo[2,3-c]pyridin-7(6h)-ones and pyrazolo[3,4-c]pyridin-7(6h)-ones as inhibitors of bet proteins
EA033459B1 (ru) 2014-05-29 2019-10-31 Entasis Therapeutics Ltd Конденсированные спироциклические гетероароматические соединения для лечения бактериальных инфекций
CA2952526A1 (en) * 2014-06-18 2015-12-23 Bayer Pharma Aktiengesellschaft Bet-protein inhibiting 3,4-dihydropyrido[2,3-b]pyrazinones with meta-substituted aromatic amino- or ether groups
US9969747B2 (en) * 2014-06-20 2018-05-15 Constellation Pharmaceuticals, Inc. Crystalline forms of 2-((4S)-6-(4-chlorophenyl)-1-methyl-4H-benzo[C]isoxazolo[4,5-e]azepin-4-yl)acetamide
WO2015195863A1 (en) 2014-06-20 2015-12-23 Constellation Pharmaceuticals, Inc. Hydrated 2-((4s)-6-(4-chlorophenyl)-1 -methyl-4h-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide
KR20170038877A (ko) * 2014-08-01 2017-04-07 누에볼루션 에이/에스 브로모도메인에 대하여 활성을 갖는 화합물
CN106715437A (zh) 2014-08-08 2017-05-24 达纳-法伯癌症研究所股份有限公司 二氮杂环庚烷衍生物及其用途
WO2016022970A1 (en) 2014-08-08 2016-02-11 Dana-Farber Cancer Institute, Inc. Dihydropteridinone derivatives and uses thereof
TWI712603B (zh) 2014-09-15 2020-12-11 美商英塞特公司 作為bet蛋白抑制劑之三環雜環
WO2016061144A1 (en) 2014-10-14 2016-04-21 The Regents Of The University Of California Use of cdk9 and brd4 inhibitors to inhibit inflammation
EA033325B1 (ru) 2014-10-27 2019-09-30 Тэнша Терапеутикс, Инк. Ингибиторы бромодомена
EP3708155A1 (en) * 2014-10-31 2020-09-16 Massachusetts Institute Of Technology Massively parallel combinatorial genetics for crispr
US10710992B2 (en) 2014-12-01 2020-07-14 Zenith Epigenetics Ltd. Substituted pyridinones as bromodomain inhibitors
EP3227280B1 (en) 2014-12-01 2019-04-24 Zenith Epigenetics Ltd. Substituted pyridines as bromodomain inhibitors
WO2016092375A1 (en) 2014-12-11 2016-06-16 Zenith Epigenetics Corp. Substituted heterocycles as bromodomain inhibitors
CN107406438B (zh) 2014-12-17 2021-05-14 恒翼生物医药科技(上海)有限公司 溴结构域的抑制剂
CN111662226B (zh) * 2015-01-28 2022-03-18 中国科学院广州生物医药与健康研究院 一种2-氧代-1,2-二氢苯并[cd]吲哚类化合物
EP3262045A1 (en) 2015-02-27 2018-01-03 The Regents of The University of Michigan 9h-pyrimido [4,5-b]indoles as bet bromodomain inhibitors
CA2977308A1 (en) 2015-03-13 2016-09-22 Resverlogix Corp. Compositions and therapeutic methods for the treatment of complement-associated diseases
EP4414369A3 (en) 2015-03-18 2024-10-16 Arvinas, Inc. Compounds and methods for the enhanced degradation of targeted proteins
GB201504694D0 (en) 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Covalent conjugates
WO2016157221A1 (en) * 2015-03-30 2016-10-06 Jubilant Biosys Limited Tricyclic fused derivatives of 1-(cyclo)alkyl pyridin-2-one useful for the treatment of cancer
WO2016196065A1 (en) 2015-05-29 2016-12-08 Genentech, Inc. Methods and compositions for assessing responsiveness of cancers to bet inhibitors
WO2016201370A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
CN107787227A (zh) 2015-06-26 2018-03-09 腾沙治疗公司 Nut中线癌的治疗
MX2018000360A (es) * 2015-07-10 2018-06-11 Arvinas Inc Moduladores basados en mdm2 de proteolisis y metodos de uso asociados.
WO2017030814A1 (en) 2015-08-19 2017-02-23 Arvinas, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
WO2017040190A1 (en) 2015-08-28 2017-03-09 Constellation Pharmaceuticals, Inc. Crystalline forms of (r)-n-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1h-indole-3-carboxamide
WO2017037567A1 (en) * 2015-09-03 2017-03-09 Pfizer Inc. Regulators of frataxin
WO2017042834A1 (en) * 2015-09-09 2017-03-16 Jubilant Biosys Limited Tricyclic fused pyridin-2-one derivatives and their use as brd4 inhibitors
EP3347020A4 (en) 2015-09-11 2019-08-14 Dana-Farber Cancer Institute, Inc. ACETAMIDE THIENOTRIAZOLDIAZEPINES AND USES THEREOF
MX2018003031A (es) 2015-09-11 2018-08-01 Dana Farber Cancer Inst Inc Ciano tienotriazolpirazinas y usos de las mismas.
AR106520A1 (es) 2015-10-29 2018-01-24 Incyte Corp Forma sólida amorfa de un inhibidor de proteína bet
WO2017091673A2 (en) 2015-11-25 2017-06-01 Dana-Farber Cancer Institute, Inc. Bivalent bromodomain inhibtors and uses thereof
ES2882066T3 (es) 2016-02-15 2021-12-01 Univ Michigan Regents 1,4-oxazepinas fusionadas y análogos relacionados como inhibidores de bromodominio BET
JP7001614B2 (ja) 2016-04-06 2022-02-03 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン リガンド依存性の標的タンパク質分解のための単官能性中間体
RU2021102253A (ru) 2016-04-06 2021-03-03 Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган Деструкторы белка mdm2
WO2017180417A1 (en) 2016-04-12 2017-10-19 The Regents Of The University Of Michigan Bet protein degraders
DE102017005091A1 (de) 2016-05-30 2017-11-30 Bayer Pharma Aktiengesellschaft Substituierte 3,4-Dihydropyrido[2,3-b]pyrazin-2(1H)-one
DE102017005089A1 (de) 2016-05-30 2017-11-30 Bayer Pharma Aktiengesellschaft Substitulerte 3,4-Dihydrochinoxalin-2(1H)-one
TWI830533B (zh) 2016-06-20 2024-01-21 美商英塞特公司 Bet抑制劑之結晶固體形式
CA3036841A1 (en) 2016-09-13 2018-03-22 The Regents Of The University Of Michigan Fused 1,4-diazepines as bet protein degraders
AU2017326171B2 (en) 2016-09-13 2021-12-09 The Regents Of The University Of Michigan Fused 1,4-oxazepines as BET protein degraders
US20190247302A1 (en) * 2016-10-21 2019-08-15 University Of Miami Materials and methods for treating ophthalmic inflammation
KR20230127371A (ko) 2016-11-01 2023-08-31 아비나스 오퍼레이션스, 인코포레이티드 타우(Tau)-단백질 표적화 프로탁(PROTAC) 및 관련 사용 방법
ES2875128T3 (es) * 2016-12-12 2021-11-08 Union Therapeutics As Pirazoloazepin-8-onas sustituidas y su uso como inhibidores de la fosfodiesterasa
RU2764273C2 (ru) * 2016-12-12 2022-01-17 Юнион Терапьютикс А/С Замещенные пиразолоазепин-8-оны и их применение в качестве ингибиторов фосфодиэстеразы
US11028051B2 (en) 2016-12-13 2021-06-08 St. Jude Children's Research Hospital Tetrahydroquinoline-based bromodomain inhibitors
EP3577120A1 (en) 2017-02-03 2019-12-11 The Regents of The University of Michigan Fused 1,4-diazepines as bet bromodomain inhibitors
JOP20190192A1 (ar) * 2017-03-01 2019-08-08 Glaxosmithkline Ip No 2 Ltd مشتقات بيرازول بوصفها مثبطات برومودومين
WO2018207881A1 (ja) * 2017-05-12 2018-11-15 武田薬品工業株式会社 複素環化合物
KR102592845B1 (ko) * 2017-05-31 2023-10-20 아유미 세이야쿠 가부시키가이샤 6H-티에노[2,3-e][1,2,4]트리아졸로[3,4-c][1,2,4]트리아제핀 유도체
US11497756B2 (en) 2017-09-12 2022-11-15 Sumitomo Pharma Oncology, Inc. Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib
WO2019055444A1 (en) 2017-09-13 2019-03-21 The Regents Of The University Of Michigan DEGRADATION AGENTS OF BROMODOMAIN BET PROTEIN WITH CLEAR BINDERS
JP7254075B2 (ja) 2017-11-06 2023-04-07 サントル ナショナル ドゥ ラ ルシェルシュ シアンティフィック キサンチン誘導体及びbetタンパク質のブロモドメインの阻害剤としてのその使用
WO2019148055A1 (en) 2018-01-26 2019-08-01 Yale University Imide-based modulators of proteolysis and methods of use
WO2020009176A1 (ja) 2018-07-04 2020-01-09 田辺三菱製薬株式会社 Bet蛋白質分解誘導作用を有するアミド化合物及びその医薬としての用途
EP3828183A4 (en) 2018-07-25 2022-03-09 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. SULFOXIMINE COMPOUND AS BROMO-DOMAIN INHIBITOR AND PHARMACEUTICAL COMPOSITION AND MEDICAL USE THEREOF
AU2018451360B2 (en) 2018-11-27 2022-05-26 Constellation Pharmaceuticals, Inc. Methods of treating myeloproliferative disorders
MX2021006205A (es) 2018-11-27 2021-10-13 Constellation Pharmaceuticals Inc Metodos de tratamiento de trastornos mieloproliferativos.
WO2021091532A1 (en) 2019-11-05 2021-05-14 Constellation Pharmaceuticals, Inc. Methods of treating myeloproliferative disorders
WO2020117988A1 (en) 2018-12-04 2020-06-11 Tolero Pharmaceuticals, Inc. Cdk9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
CN111518045A (zh) * 2019-02-02 2020-08-11 博诺康源(北京)药业科技有限公司 一种具有苯并七元环结构的化合物、其制备方法及用途
JP2022525149A (ja) 2019-03-20 2022-05-11 スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド ベネトクラクスが失敗した急性骨髄性白血病(aml)の処置
WO2020256739A1 (en) 2019-06-21 2020-12-24 Constellation Pharmaceuticals, Inc. Methods of treating myeloproliferative disorders
WO2020257644A1 (en) 2019-06-21 2020-12-24 Constellation Pharmaceuticals, Inc. Methods of treating myeloproliferative disorders
WO2021091535A1 (en) 2019-11-05 2021-05-14 Constellation Pharmaceuticals, Inc. Treating myeloproliferative disorders with cpi-0610 and a jak inhibitor
CN112142711B (zh) * 2019-06-28 2022-03-29 中国科学院上海药物研究所 取代噻吩类化合物、其制备方法及其用途
US11912699B2 (en) 2019-07-17 2024-02-27 Arvinas Operations, Inc. Tau-protein targeting compounds and associated
EP4003342A1 (en) * 2019-07-29 2022-06-01 Constellation Pharmaceuticals, Inc. Compounds for use in treating neurological disorders
US11883393B2 (en) 2019-12-19 2024-01-30 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
MX2022009700A (es) 2020-02-06 2022-09-07 Mitsubishi Tanabe Pharma Corp Compuesto de sulfonamida o sulfinamida que tiene el efecto de inducir la degradacion de la proteina de bromodominio 4 (brd4) y el uso farmaceutico del mismo.
WO2021175432A1 (en) 2020-03-04 2021-09-10 Boehringer Ingelheim International Gmbh Method for administration of an anti cancer agent
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
CN115702026A (zh) 2020-06-23 2023-02-14 基因泰克公司 大环化合物及其使用方法
KR20230048042A (ko) 2020-08-04 2023-04-10 콘스텔레이션 파마슈티칼스, 인크. 혈소판 증가증의 치료를 위한 2-((4s)-6-(4-클로로페닐)-1-메틸-4h-벤조[c]이속사졸로[4,5-e]아제핀-4-일)아세트아미드
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
JP2024517472A (ja) 2021-05-11 2024-04-22 コンステレーション・ファーマシューティカルズ・インコーポレイテッド 貧血を処置するためのペラブレシブの使用
KR102619332B1 (ko) * 2021-11-30 2024-01-02 주식회사 베노바이오 Bet 단백질을 저해하는 신규한 카르복스아마이드 리독스 유도체 및 이를 이용한 안과질환 예방 및 치료용 조성물
IL314479A (en) 2022-01-31 2024-09-01 Constellation Pharmaceuticals Inc Anhydrous crystalline forms of 2-((4S)-6-(4-chlorophenyl)-1-methyl-4H-benzo[C]isoxazolo[5,4-E]azepin-4-yl)acetamide
AU2023255396A1 (en) 2022-04-19 2024-10-24 Nuevolution A/S Compounds active towards bromodomains
WO2024137713A1 (en) 2022-12-20 2024-06-27 Constellation Pharmaceuticals, Inc. Methods for treating lower risk myelodysplastic syndrome

Family Cites Families (142)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3523939A (en) 1967-07-03 1970-08-11 Hoffmann La Roche 5-(2,6-disubstituted phenyl)-1,4-benzodiazepines and methods for their preparation
CH498846A (de) 1967-08-09 1970-11-15 Hoffmann La Roche Verfahren zur Herstellung von Benzodiazepin-Derivaten
US3781289A (en) 1971-02-09 1973-12-25 Upjohn Co 7-chloro-1-methyl-5-phenyl-s-triazolo (4,3-a)quinolines
US3709898A (en) 1971-02-09 1973-01-09 Upjohn Co Process for the production of triazolobenzodiazepines and intermediates
US3681343A (en) 1971-05-11 1972-08-01 Upjohn Co 6-phenyl-s-triazolo{8 4,3-a{9 {8 1,4{9 {0 benzodiazepines
DE2242918A1 (de) 1971-09-15 1973-03-22 Upjohn Co Neue 4-amino-s-triazolo eckige klammer auf 4,3-a eckige klammer zu eckige klammer auf 1,4 eckige klammer zu benzodiazepine
US3903103A (en) 1971-09-15 1975-09-02 Upjohn Co 4-Amino-s-triazolo-{8 4,3-a{9 {8 1,4{9 benzodiazepine
US3886141A (en) 1971-10-07 1975-05-27 Hoffmann La Roche Preparation of 5-pyridyl benzodiazepine utilizing hexamethylenetetramine
BE795790A (fr) 1972-02-22 1973-08-22 Upjohn Co Dibenzo-triazolo-azepine
US4155904A (en) 1973-02-08 1979-05-22 Schering Corporation Process for the preparation of 1,4-benzo-diazepines and 1,4-benzodiazepinones
FR2220257A1 (en) 1973-03-09 1974-10-04 Lipha 5,6-Dihydro-(4H)-s-triazolo-(4,3-a) (1,5)benzodiazepines - as antiinflam-matory and analgesic agents without tranquillising effects
IE38931B1 (en) 1973-03-09 1978-07-05 Lipha Triazolobenzodiazepines
US3966736A (en) 1975-04-07 1976-06-29 The Upjohn Company 2,9-Dihydro-3H-pyrido[3,2-c]-s-triazolo[4,3-a][1,5]-benzodiazepin-3-ones
AT350056B (de) 1975-11-04 1979-05-10 Degussa Verfahren zur herstellung von neuen pyrido- (2,3-f)-(1,4)-diazepinen, deren optischen isomeren und salzen
DE2640599A1 (de) 1976-09-09 1978-03-16 Scherico Ltd Verfahren zur herstellung von 1,4- benzodiazepinen
CA1152066A (en) 1980-02-08 1983-08-16 Hoffmann-La Roche Limited Benzodiazepine derivatives
CA1157855A (en) 1980-07-31 1983-11-29 Albert E. Fischli Benzodiazepine derivatives
CA1163266A (en) 1980-07-31 1984-03-06 Albert E. Fischli Benzodiazepine derivatives
US4455307A (en) 1982-01-04 1984-06-19 The Upjohn Company Antihypertensive use of triazolobenzodiazepines
US4663321A (en) 1984-06-26 1987-05-05 Merck & Co., Inc. Triazolobenzodiazepines and pharmaceutical use
US5004741A (en) 1984-06-26 1991-04-02 Merck & Co., Inc. Methods of antagonizing CCK or gastrin with benzodiazepine analogs
US4820834A (en) 1984-06-26 1989-04-11 Merck & Co., Inc. Benzodiazepine analogs
WO1988009333A1 (en) 1987-05-28 1988-12-01 Yoshitomi Pharmaceutical Industries, Ltd. Thieno(triazolo)diazepine compound and medicinal application of the same
MC1999A1 (fr) 1987-12-18 1990-01-26 Hoffmann La Roche Composes tricycliques
US4959361A (en) 1987-12-18 1990-09-25 Hoffmann-La Roche Inc. Triazolo(4,3-A)(1,4)benzodiazepines and thieno (3,2-F)(1,2,4)triazolo(4,3-A)(1,4)diazepine compounds which have useful activity as platelet activating factor (PAF) antagonists
US4992437A (en) 1987-12-22 1991-02-12 Yoshitomi Pharmaceutical Industries, Ltd. Thienodiazepine compounds and their pharmaceutical use
CA1324863C (en) 1988-01-30 1993-11-30 Minoru Moriwaki Thienotriazolodiazepine compounds and pharmaceutical uses thereof
CA1322367C (en) 1988-05-17 1993-09-21 Yoshitomi Pharmaceutical Industries Ltd. Thienotriazolodiazepine compounds and pharmaceutical uses thereof
US5221671A (en) 1988-10-31 1993-06-22 Eisai Co., Ltd. Triazolo-1,4-diazepine derivatives and their use in pharmaceuticals
FI95708C (fi) 1988-10-31 1996-03-11 Eisai Co Ltd Analogiamenetelmä 1,4-diatsepiinijohdannaisen ja sen farmaseuttisesti sopivan suolan valmistamiseksi
US5382579A (en) 1988-10-31 1995-01-17 Eisai Co., Ltd. Triazolo-1,4-diazepine derivatives and their use in pharmaceuticals
DE3936828A1 (de) 1988-11-06 1990-05-10 Boehringer Ingelheim Kg Neue hetrazepine
DE4006471A1 (de) 1989-03-03 1990-09-06 Boehringer Ingelheim Kg Neue thienodiazepine
CA2020806A1 (en) 1989-07-12 1991-01-13 Karl-Heinz Weber Thienodiazepine derivatives
JPH0374328A (ja) 1989-08-04 1991-03-28 Warner Lambert Co 薬学的活性を有する中枢コレシストキニン拮抗剤
US5175159A (en) 1989-10-05 1992-12-29 Merck & Co., Inc. 3-substituted-1,4-benzodiazepines as oxytocin antagonists
IL96613A0 (en) 1989-12-18 1991-09-16 Merck & Co Inc Pharmaceutical compositions containing benzodiazepine analogs
CA2032427A1 (en) 1989-12-18 1991-06-19 Mark G. Bock Benzodiazepines analogs
JP2971902B2 (ja) 1990-03-15 1999-11-08 エーザイ株式会社 トリアゾロ―1,4―ジアゼピン系化合物
JP2971901B2 (ja) 1990-03-15 1999-11-08 エーザイ株式会社 トリアゾロ―1,4―ジアゼピン系化合物
WO1994006801A1 (en) 1990-05-23 1994-03-31 Yoshitomi Pharmaceutical Industries, Ltd. Thienodiazepine compound and medicinal use thereof
JP2959591B2 (ja) 1990-05-23 1999-10-06 吉富製薬株式会社 チエノトリアゾロジアゼピン化合物
DE4027470A1 (de) 1990-08-30 1992-03-05 Boehringer Ingelheim Kg Neue hetrazepinoide amide
JP2959598B2 (ja) 1990-10-12 1999-10-06 吉富製薬株式会社 光学活性なチエノトリアゾロジアゼピン化合物
US5206234A (en) 1990-10-22 1993-04-27 Merck & Co., Inc. Benzolactam analogs as antagonists of cck
CA2056809A1 (en) 1990-12-07 1992-06-08 Mark G. Bock Benzodiazepine analogs
DE4101146A1 (de) 1991-01-16 1992-07-23 Boehringer Ingelheim Kg Neue in 6-position substituierte diazepine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE4107521A1 (de) 1991-03-08 1992-09-10 Boehringer Ingelheim Kg Neue acylaminosubstituierte hetrazepine
US5683998A (en) 1991-04-23 1997-11-04 Toray Industries, Inc. Tricyclic triazolo derivatives, processes for producing the same and the uses of the same
US5185331A (en) 1991-05-14 1993-02-09 Merck & Co., Inc. Triazolobenzodiazepines
EP0523846A3 (en) 1991-06-14 1993-03-17 Merck & Co. Inc. 1,4-benzodiazepines with 5-membered heterocyclic rings
GB9117852D0 (en) 1991-08-19 1991-10-09 Merck Sharp & Dohme Therapeutic agents
US5153191A (en) 1991-08-20 1992-10-06 Warner-Lambert Company Cholecystokinin antagonists useful for treating depression
DE4128581A1 (de) 1991-08-28 1993-03-04 Boehringer Ingelheim Kg Verwendung von paf-antagonisten hetrazepinoider struktur zur behandlung der allergischen rhinitis
WO1993007152A1 (fr) 1991-09-30 1993-04-15 Yoshitomi Pharmaceutical Industries, Ltd. Compose a base de thienodiazepine et son utilisation
EP0638560A4 (en) 1991-10-11 1995-03-29 Yoshitomi Pharmaceutical MEDICINE FOR OSTEOPOROSIS AND DIAZEPINE COMPOUND *.
EP0656361B1 (en) 1991-12-11 2000-04-05 Yoshitomi Pharmaceutical Industries, Ltd. Autoimmune disease treating drug
WO1993012791A1 (en) 1991-12-20 1993-07-08 Merck Sharp & Dohme Limited Central cholecystokinin antagonists having pharmaceutical activity
DE4200610A1 (de) 1992-01-13 1993-07-15 Boehringer Ingelheim Kg Verwendung von paf-antagonisten zur behandlung der dysmenorrhea
WO1993019052A1 (en) 1992-03-24 1993-09-30 Merck Sharp & Dohme Limited 3-ureido substituted benzodiazepin-2-ones having cholecystokinin and/or gastrin antagonistic activity and their use in therapy
DE4219659A1 (de) 1992-06-16 1993-12-23 Boehringer Ingelheim Kg Die Verwendung von PAF-Antagonisten in Kombination mit Anticholinergika
WO1994006802A1 (en) 1992-09-18 1994-03-31 Yoshitomi Pharmaceutical Industries, Ltd. Thienodiazepine compound and medicinal use thereof
JP3223290B2 (ja) 1992-11-10 2001-10-29 日本電信電話株式会社 マイクロ回転体およびその製造方法
US5302590A (en) 1992-12-18 1994-04-12 Hoffmann-La Roche Inc. Compounds useful as dual antagonists of platelet activating factor and leukotriene D4
CA2159344A1 (en) 1993-03-30 1994-10-13 Minoru Moriwaki Cell adhesion inhibitor and thienotriazolodiazepine compound
US5843941A (en) 1993-05-14 1998-12-01 Genentech, Inc. Ras farnesyl transferase inhibitors
US5760031A (en) 1993-07-29 1998-06-02 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US5733905A (en) 1993-07-29 1998-03-31 American Cyanamid Company Tricyclic diazepine vasopressin antagonists and oxytocin antagonists
US5516774A (en) 1993-07-29 1996-05-14 American Cyanamid Company Tricyclic diazepine vasopressin antagonists and oxytocin antagonists
US5869483A (en) 1993-07-29 1999-02-09 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
CA2176020A1 (en) 1993-11-22 1995-06-01 John J. Baldwin Benzodiazepines
DE69427023T2 (de) 1993-12-28 2001-10-31 Meiji Seika K.K., Tokio/Tokyo Tricyclische benzazepin-und benzothiazepin derivate
US5739129A (en) 1994-04-14 1998-04-14 Glaxo Wellcome Inc. CCK or gastrin modulating 5-heterocyclic-1, 5 benzodiazepines
US5795887A (en) 1994-04-15 1998-08-18 Glaxo Wellcome Inc. Method of inducing cholecystokinin agonist activity using 1,4- Benzodiazepine compounds
EA002123B1 (ru) 1995-09-21 2001-12-24 Инститьют Оф Медисинал Молекъюла Дизайн, Инк. Соединения, усиливающие активность ретиноидов
IL127516A0 (en) * 1996-06-12 1999-10-28 Japan Tobacco Inc A cytokine production inhibitor
PT989131E (pt) 1996-09-13 2003-03-31 Mitsubishi Pharma Corp Compostos de trienotriazolodiazepina e suas utilizacoes com fins medicinais
CN1616432A (zh) 1996-12-23 2005-05-18 伊兰药品公司 化合物、其用途以及含有所述化合物的药物组合物
US6433167B1 (en) 1997-06-25 2002-08-13 Nikken Chemicals Co., Ltd. Triazolo-1,4-diazepine compounds and medicinal composition containing the same
JP4204657B2 (ja) 1997-12-05 2009-01-07 有限会社ケムフィズ 糖尿病の予防・治療剤
JPH11228576A (ja) 1997-12-10 1999-08-24 Japan Tobacco Inc アポトーシス抑制剤
FR2779652B1 (fr) 1998-06-15 2001-06-08 Sod Conseils Rech Applic Utilisation de diazepines pour la preparation de medicaments destines a traiter les etats pathologiques ou les maladies dans lesquels un des recepteurs de la somatostatine est implique
PE20000944A1 (es) 1998-07-31 2000-09-20 Lilly Co Eli Derivados de sulfonamida
WO2000012547A2 (en) 1998-09-01 2000-03-09 Innogenetics N.V. Benzodiazepines and benzothiazepines derivatives and hbsag peptides binding to annexins, their compositions and use
US6277844B1 (en) * 1998-09-14 2001-08-21 Sydney Spector Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis
AU2939000A (en) 1999-03-12 2000-10-04 Welfide Corporation Preventive or therapeutic agents for inflammatory dermatoses
FR2791980B1 (fr) 1999-04-09 2001-07-06 Sod Conseils Rech Applic Pyrido-thieno-diazepines, leur procede de preparation, et les compositions pharmaceutiques les contenant
GB9911152D0 (en) 1999-05-14 1999-07-14 Glaxo Group Ltd Short-acting benzodiazepines
US7160880B1 (en) 1999-05-14 2007-01-09 Cenes Limited Short-acting benzodiazepines
WO2001047510A2 (en) 1999-12-29 2001-07-05 Glaxo Group Limited Methods and compositions related to modulators of annexin and cartilage homeostasis
JP4875277B2 (ja) 2000-06-16 2012-02-15 田辺三菱製薬株式会社 放出pH域及び/又は速度制御組成物
CA2446696A1 (fr) 2001-06-07 2002-12-12 Neuro3D Inhibiteurs des phosphodiesterases des nucleotides cycliques, preparation et utilisations de ces inhibiteurs
KR20040087335A (ko) 2002-03-01 2004-10-13 야마노우치세이야쿠 가부시키가이샤 질소 함유 복소환 화합물
DE60324449D1 (de) 2002-10-30 2008-12-11 Via Pharmaceuticals Inc Inhibitoren der phosphodiesterase der zyklischen n, und deren verwendung in therapie
DE10251927A1 (de) 2002-11-08 2004-05-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
US7482337B2 (en) 2002-11-08 2009-01-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
WO2004058769A2 (en) 2002-12-18 2004-07-15 Vertex Pharmaceuticals Incorporated Triazolopyridazines as protein kinases inhibitors
US7119088B2 (en) 2003-02-19 2006-10-10 Pfizer Inc. Triazole compounds useful in therapy
EP1640010A1 (en) 2003-07-01 2006-03-29 Astellas Pharma Inc. Agent inducing increase in bone mass
WO2005099759A1 (ja) 2004-04-16 2005-10-27 Institute Of Medicinal Molecular Design. Inc. 動脈硬化症の予防及び/又は治療のための医薬
JP4494414B2 (ja) 2004-10-05 2010-06-30 パイオニア株式会社 オーディオラック
EP1887008B1 (en) 2005-05-30 2021-04-21 Mitsubishi Tanabe Pharma Corporation Thienotriazolodiazepine compound and a medicinal use thereof
WO2007016087A2 (en) 2005-07-29 2007-02-08 Merck & Co., Inc. Heterocyclic benzodiazepine cgrp receptor antagonists
US20070105844A1 (en) 2005-10-26 2007-05-10 Regents Of The University Of Michigan Therapeutic compositions and methods
AU2006306347A1 (en) 2005-10-26 2007-05-03 The Regents Of The University Of Michigan Therapeutic compositions and methods
DE102005061840A1 (de) 2005-12-23 2007-06-28 Merck Patent Gmbh Triazolderivate
WO2008023847A1 (fr) 2006-08-25 2008-02-28 Nippon Chemiphar Co., Ltd. Antagoniste du récepteur p2x4
WO2008109856A2 (en) 2007-03-07 2008-09-12 Xenon Pharmaceuticals Inc. Methods of using diazepinone compounds in treating sodium channel-mediated diseases or conditions
US20090111780A1 (en) 2007-10-31 2009-04-30 Everett Laboratories, Inc. Compositions and methods for treatment of ear canal infection and inflammation
ITFI20070288A1 (it) 2007-12-21 2009-06-22 A I L Firenze Sezione Autonoma Inibitori delle deacetilasi istoniche
CN101910182B (zh) * 2007-12-28 2013-07-17 田边三菱制药株式会社 抗癌剂
EP2349257B1 (en) 2008-06-17 2013-11-27 Universidade Federal de Minas Gerais-UFMG Use of paf receptor for treating infections caused by flaviviridae
JP5634990B2 (ja) 2008-06-23 2014-12-03 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated タンパク質キナーゼ阻害剤
EP2362876B1 (en) 2008-10-30 2013-12-11 Circomed LLC Thienotriazolodiazepine derivatives active on apo a
US8604023B2 (en) 2009-04-17 2013-12-10 The Regents Of The University Of Michigan 1,4-benzodiazepinone compounds and their use in treating cancer
JP5768239B2 (ja) 2009-05-07 2015-08-26 株式会社 PRISM BioLab アルファへリックスミメティック及び関連の方法
KR101435729B1 (ko) 2009-09-28 2014-09-01 닛뽕소다 가부시키가이샤 함질소 헤테로 고리 화합물 및 그의 염, 그리고 농원예용 살균제
GB0919431D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919426D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
JP5702396B2 (ja) 2009-11-05 2015-04-15 グラクソスミスクライン エルエルシー ベンゾジアゼピンブロモドメイン阻害剤
RS53179B (en) 2009-11-05 2014-06-30 Glaxosmithkline Llc BENZODIAZEPINSKI INHIBITOR BROMODOMENA
GB0919423D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
EP2496945B1 (en) 2009-11-05 2015-04-01 GlaxoSmithKline LLC Novel process
GB0919432D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Use
GB0919434D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
WO2011079315A1 (en) 2009-12-23 2011-06-30 The Scripps Research Institute Tyrosine bioconjugation through aqueous ene-like reactions
TW201201813A (en) 2010-03-31 2012-01-16 Arqule Inc Substituted benzo-pyrido-triazolo-diazepine compounds
DK2571503T3 (en) 2010-05-14 2015-04-20 Dana Farber Cancer Inst Inc COMPOSITIONS AND THEIR USE IN THE TREATMENT OF NEOPLASIA, INFLAMMATORY DISEASE AND OTHER DISORDERS
US20130252331A1 (en) 2010-05-14 2013-09-26 James Elliott Bradner Compositions and methods for modulating metabolism
CA2799381A1 (en) 2010-05-14 2011-11-17 Dana-Farber Cancer Institute, Inc. Male contraceptive compositions and methods of use
JP5935030B2 (ja) 2010-05-14 2016-06-15 ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド 白血病を治療するための組成物および方法
US9085582B2 (en) 2010-06-22 2015-07-21 Glaxosmithkline Llc Benzotriazolodiazepine compounds inhibitors of bromodomains
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
WO2012075456A1 (en) 2010-12-02 2012-06-07 Constellation Pharmaceuticals Bromodomain inhibitors and uses thereof
US9422292B2 (en) 2011-05-04 2016-08-23 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
GB201114103D0 (en) 2011-08-17 2011-09-28 Glaxosmithkline Llc Novel compounds
WO2013033268A2 (en) 2011-08-29 2013-03-07 Coferon, Inc. Bivalent bromodomain ligands, and methods of using same
WO2013033269A1 (en) 2011-08-29 2013-03-07 Coferon, Inc. Bioorthogonal monomers capable of dimerizing and targeting bromodomains and methods of using same
WO2013033420A1 (en) 2011-08-30 2013-03-07 Whitehead Institute For Biomedical Research Methods of downregulating translocated oncogene expression using bromodomain inhibitors
DE102011082013A1 (de) 2011-09-01 2013-03-07 Bayer Pharma AG 6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine
TWI602820B (zh) * 2012-06-06 2017-10-21 星宿藥物公司 溴域抑制劑及其用途
WO2013184878A1 (en) 2012-06-06 2013-12-12 Constellation Pharmaceuticals, Inc. Benzo [b] isoxazoloazepine bromodomain inhibitors and uses thereof

Also Published As

Publication number Publication date
RS54175B1 (en) 2015-12-31
PL2646446T3 (pl) 2015-10-30
SI2646446T1 (sl) 2015-09-30
PT2646446E (pt) 2015-09-24
EA022645B1 (ru) 2016-02-29
CN103415525A (zh) 2013-11-27
US20120157428A1 (en) 2012-06-21
ZA201303776B (en) 2014-11-26
AU2011336417A1 (en) 2013-07-04
US20140371206A1 (en) 2014-12-18
EA201390803A1 (ru) 2013-09-30
CA2818187C (en) 2018-10-23
HK1189587A1 (en) 2014-06-13
ES2545117T3 (es) 2015-09-08
WO2012075383A3 (en) 2012-08-16
EP2646446A2 (en) 2013-10-09
TWI572607B (zh) 2017-03-01
BR112013013167A2 (pt) 2017-10-31
AR084070A1 (es) 2013-04-17
EP2646446B1 (en) 2015-05-13
KR101871013B1 (ko) 2018-07-20
KR20130125378A (ko) 2013-11-18
IL226331A0 (en) 2013-07-31
MX2013006214A (es) 2014-10-17
CN103415525B (zh) 2016-05-18
JP2013544847A (ja) 2013-12-19
WO2012075383A2 (en) 2012-06-07
JP5850944B2 (ja) 2016-02-03
IL226331A (en) 2015-09-24
HUE025321T2 (en) 2016-02-29
NZ611964A (en) 2015-01-30
HRP20150858T1 (hr) 2015-09-25
US9522920B2 (en) 2016-12-20
AU2011336417B2 (en) 2016-09-29
BR112013013167A8 (pt) 2021-05-18
US8796261B2 (en) 2014-08-05
CA2818187A1 (en) 2012-06-07
TW201305182A (zh) 2013-02-01
SG190739A1 (en) 2013-07-31
EP2646446A4 (en) 2014-04-23
BR112013013167B1 (pt) 2021-12-07
DK2646446T3 (en) 2015-08-10

Similar Documents

Publication Publication Date Title
CY1116578T1 (el) Αναστολεις της bromodomain και χρησεις αυτων
CY1124311T1 (el) Παρεμποδιστες dna-pk
CY1125436T1 (el) Αναστολεις dna-pk
EA201492216A1 (ru) Ингибиторы бромодомена и их применение
CY1123470T1 (el) Αναστολεις ιβατ για την αγωγη ηπατοπαθειων
CY1123552T1 (el) Θεραπειες συνδυασμου με χρηση μοριων προσδεσης psl και pcrv αντι- pseudomonas
CY1117471T1 (el) Αμιδια πυρρολοπυραζινης-σπειροκυκλικης πιπεριδινης ως ρυθμιστες διαυλων ιοντος
EA201591591A1 (ru) Соединения карбазола, применяемые в качестве ингибиторов бромодомена
CY1120035T1 (el) Πυριμιδοπυριμιδινονες χρησιμες ως αναστολεις της wee-1 κινασης
EA201391285A1 (ru) Производные тетрагидрохинолина, полезные в качестве ингибиторов бромодомена
CY1116435T1 (el) Ενωσεις βορονικου εστερα και φαρμακευτικες συνθεσεις αυτων
EA202193044A2 (ru) Способы лечения таупатии
CY1118454T1 (el) Πρωτοτυποι αναστολεις πυρρολιου της αναγωγασης s-νιτροζογλουταθειονης ως θεραπευτικοι παραγοντες
CY1118680T1 (el) Φαρμακευτικη συνθεση
CY1114988T1 (el) Βενζοδιαζεπινη αναστολεας bromodomain
WO2012174487A8 (en) Bromodomain inhibitors and uses thereof
EA201390929A1 (ru) Антитела к pcsk9 и способы их применения
WO2012151512A3 (en) Bromodomain inhibitors and uses thereof
CY1113386T1 (el) Αναστολεις πρωτεασωματος
EA201391507A1 (ru) АНТИТЕЛА ПРОТИВ c-Kit И ИХ ПРИМЕНЕНИЕ
EA201290980A1 (ru) Производные 1-амино-2-циклопропилэтилбороновой кислоты
JO3118B1 (ar) تراكيب وطرق لبروتين c5 المتمم يستهدف الأجسام المضادة
CY1123490T1 (el) Συνθεσεις που προερχονται απο χιτοζανη
EA201490778A1 (ru) АНТИТЕЛА ПРОТИВ HtrA1 И СПОСОБЫ ПРИМЕНЕНИЯ
EA201391274A1 (ru) Аминохинолины в качестве ингибиторов киназ